Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY (BLADE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02645799
Recruitment Status : Unknown
Verified January 2018 by BIOrest Ltd..
Recruitment status was:  Active, not recruiting
First Posted : January 5, 2016
Last Update Posted : January 11, 2018
Sponsor:
Information provided by (Responsible Party):
BIOrest Ltd.

Brief Summary:

The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post procedure in patients with diabetes mellitus (DM).

Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in patients with DM.


Condition or disease Intervention/treatment Phase
Diabetes Mellitus Drug: LABR-312 Drug: Saline (placebo) Phase 2

Detailed Description:

This is a phase IIb, prospective, multi-center, multi-national, randomized, double-blind, two-arm, 1:1 (escalating dose LABR-312 vs. placebo) clinical trial.

In both study arms, all target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.

Lesions that are planned to be treated must be declared and recorded at the time of randomization.

Randomization will be stratified by the presence or absence of insulin treatment, HbA1c level (<7.5% vs. ≥7.5%), and by pre-procedure monocyte count (≥500/uL or below).

Subjects (n=~270) will be randomized to receive either the study drug LABR-312 or the placebo. Conditionally to ongoing safety monitoring, dose escalation of LABR-312 in the study arm will be performed: 0.01 mg (first 45 patients vs. 45 patients receiving placebo), up to 0.03 mg (next consecutive 45 patients vs. 45 patients receiving placebo) and up to 0.08 mg (final 45 consecutive patients vs. 45 patients receiving placebo). If a decision is made not to dose escalate, recruitment will continue with the highest dose level deemed safe by the ongoing safety monitoring, until approximately 270 subjects are randomized.

In the LABR-312 group, 3 doses will therefore be tested, resulting in 6 possibilities:

Group 1: Low dose 0.01 mg LABR-312 or equivalent volume of placebo (saline) administered IV.

Group 2: Intermediate dose Up to 0.03 mg LABR-312 or equivalent volume of placebo (saline) administered IV.

Group 3: High dose Up to 0.08 mg LABR-312 or equivalent volume of placebo (saline) administered IV.

The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1year post randomization.

OCT follow-up will be performed at 9 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention
Study Start Date : April 2016
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : November 2018

Arm Intervention/treatment
Active Comparator: LABR-312

LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.

Three (3) doses will be tested:

Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.

OCT follow-up will be performed at 9 months.

Drug: LABR-312
administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent

Placebo Comparator: saline

Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.

Three (3) doses will be tested:

Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.

OCT follow-up will be performed at 9 months.

Drug: Saline (placebo)
administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent




Primary Outcome Measures :
  1. %NIH volume [ Time Frame: at 9 months ]
    NIH volume/stent volume × 100 at 9 months as measured by the OCT core laboratory (all doses pooled vs. placebo).


Secondary Outcome Measures :
  1. %NIH at minimum lumen area (MLA) site [ Time Frame: 9 months ]
    Secondary OCT endpoint evaluated at 9 months as measured by the OCT core laboratory

  2. MLA [ Time Frame: 9 months ]
    Secondary OCT endpoint evaluated at 9 months as measured by the OCT core laboratory

  3. % area stenosis [ Time Frame: 9 months ]
    Secondary OCT endpoint evaluated at 9 months as measured by the OCT core laboratory

  4. % stent strut coverage [ Time Frame: 9 months ]
    Secondary OCT endpoint evaluated at 9 months as measured by the OCT core laboratory

  5. In-stent late loss [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  6. In-segment percent diameter stenosis (%DS) (within 5mm margins proximal and distal to stent) [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  7. In-stent %DS [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  8. In-segment late loss [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  9. In-stent late loss compared between the 3 doses of the study drug [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  10. In-segment binary restenosis (stenosis of >50% of the vessel diameter) [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  11. In-stent minimum lumen diameter (MLD) [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  12. Length and patterns of angiographic restenosis (Mehran classification) [ Time Frame: 9 months ]
    Secondary angiographic endpoint evaluated at 9 months

  13. MACE [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: The composite rate of cardiac death, any MI or ischemia-driven TLR

  14. Clinically driven TLR [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: Defined as re-intervention (PCI or CABG) due to stenosis of ≥50% at the level of the index-targeted lesion(s) (inside 5mm proximal and distal to the implanted stent), by quantitative coronary angiography (QCA), with ischemic signs and/or symptoms

  15. Clinically driven target vessel revascularization (TVR) [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: Defined as re-intervention (PCI or CABG) due to stenosis of ≥50% inside the targeted epicardial vessel, by QCA, with ischemic signs and/or symptoms

  16. TVF [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: Defined as the composite of cardiac death, target vessel MI, or clinically driven TVR

  17. TLF [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: Defined as the composite of cardiac death, target vessel MI, or clinically driven TLR

  18. Target Vessel Related MI [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: The number of patients who suffer a MI that is related to the target vessel of the procedure.

  19. Stroke [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: Major, minor and transient ischemic attack; secondary clinical endpoint evaluated at 30 days, 9 months, and 1 year post procedure

  20. All death [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: The number of patients who die from all causes

  21. MI [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: The number of patients who suffer a myocardial infarction

  22. Composite endpoint of cardiac death or MI [ Time Frame: 30 days, 9 months, 1 year ]
    Clinical: The number of patients who die of cardiac-related causes or myocardial infarction

  23. Definite or probable ARC defined stent thrombosis [ Time Frame: 30 days, 9 months, 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria: all must be present

  1. Patient has medically treated diabetes mellitus (is on insulin or oral or injectable hypoglycemic medications).
  2. Patient is eligible and has an indication for PCI with a drug eluting stent (patient may be consented prior to diagnostic angiography with possible PCI).
  3. Patient presents with angina (stable or unstable), silent ischemia (in absence of symptoms must have a positive stress test, FFR ≤0.80, or angiographic stenosis of ≥70%), NSTEMI, or recent STEMI (>7 days from procedure).
  4. Non-target vessel PCI are allowed prior to randomization depending on the time interval and conditions as follows:

    • During Baseline Procedure:
    • PCI of non-target vessels performed during the baseline procedure itself immediately prior to randomization, if successful and uncomplicated, defined as: <50% visually estimated residual diameter stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C, no perforation, no persistent ST segment changes, no prolonged chest pain, no TIMI major or BARC type 3 bleeding.

      • Less than 24 hours prior to Baseline Procedure:
    • Not allowed (see exclusion criteria #2).

      • 24 hours-30 days prior to Baseline Procedure:
    • PCI of non-target vessels 24 hours to 30 days prior to randomization if successful and uncomplicated as defined above.
    • In cases where non-target lesion PCI has occurred 24-72 hours prior to the baseline procedure, at least 2 sets of cardiac biomarkers must be drawn at least 6 and 12 hours after the non-target vessel PCI.
    • If cardiac biomarkers are initially elevated above the local laboratory upper limit of normal, serial measurements must demonstrate that the biomarkers are falling.

      • Over 30 days prior to Baseline Procedure:
    • PCI of non-target vessels performed greater than 30 days prior to procedure whether or not successful and uncomplicated.
  5. All non-target lesions (i.e. those not meeting angiographic criteria for the study) should be treated prior to randomization. All target lesions must be planned to be treated during the index procedure. The investigator will declare which target lesions are intended for treatment at the time of randomization. In the event that all target lesions cannot be treated (e.g. due to contrast load), staged procedure should be delayed preferably at least 2 weeks after the index PCI, and those lesions will be considered non-target lesions. Any such planned staged lesions must be declared at the end of the index procedure.
  6. Prior target-vessel PCI is allowed if it occurred ≥6 months prior to randomization and no restenosis is present, or if re-intervention is planned on the restenotic lesion(s) as a non-target lesion.
  7. The patient or legal guardian is willing and able to provide written informed consent and comply with follow-up visits and the testing schedule.

Angiographic Inclusion Criteria (visual estimate) (all must be present):

  1. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥2.25mm to ≤4.2mm and diameter stenosis ≥50% to <100%.
  2. Thrombolysis in Myocardial Infarction (TIMI) flow 2 or 3. If more than 1 target lesion will be treated, the reference vessel diameter and lesion length of each must meet the above criteria.

General Exclusion Criteria: all must be absent

  1. STEMI within 7 days of presentation to the first treating hospital, whether a transfer facility or the study hospital
  2. PCI within the 24 hours prior to randomization
  3. Cardiogenic shock (defined as persistent hypotension [systolic blood pressure <90 mm Hg] or requiring pressors or hemodynamic support, including IABP)
  4. Known left ventricular ejection fraction <30%
  5. Relative or absolute contraindication to DAPT for 6 months (including planned surgeries that cannot be delayed or chronic oral anticoagulant requirement, such as atrial fibrillation or prosthetic heart valve)
  6. Hemoglobin <10 g/dL
  7. Platelet count <100,000 cells/mm3 or >700,000 cells/mm3
  8. White blood cell count <3,000 cells/mm3
  9. Major and clinically significant active infection
  10. Clinically significant liver disease
  11. Renal insufficiency as defined by an estimated Glomerular Filtration Rate, GFR <40 ml/min by the MDRD formula
  12. Active peptic ulcer or active bleeding from any site
  13. Bleeding from any site requiring active medical attention within the prior 8 weeks
  14. History of bleeding diathesis or coagulopathy or likely to refuse blood transfusions
  15. Cerebrovascular accident (CVA) or has any permanent neurological defect as a result of CVA
  16. Known allergy to the study stent components or protocol-required concomitant medications: alendronate, liposomal medications, aspirin, clopidogrel and prasugrel and ticagrelor, heparin and bivalirudin, or iodinated contrast that cannot be adequately pre-medicated
  17. Subject is taking Bisphosphonates, including Alendronate (Fosamax); Clodronate (Bonefos); Etidronate (Didronel / Didrocal); Ibandronate (Bondronat); Pamidronate (Aredia); Risedronate (Actonel); Tiludronate (Skelid); Zoledronic acid (Zometa), or any other bisphosphonates not listed above.
  18. Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.) or reduce life expectancy to <24 months (e.g. cancer, heart failure, lung disease)
  19. Patient is participating in or plans to participate in any other investigational drug or device trial that has not reached its primary endpoint.
  20. Women who are pregnant or breastfeeding (women of child-bearing potential must have a negative pregnancy test within one week before index procedure).
  21. Women who intend to become pregnant within 12 months after the index procedure
  22. Patient has received an organ transplant or is on a waiting list for an organ transplant.
  23. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any time after the index procedure.
  24. Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease. Inhaled steroid and steroid use for contrast-allergy prophylaxis or treatment are allowed.

Angiographic Exclusion Criteria (visual estimate) (all must be absent):

  1. Unprotected left main lesions >30% or left main intervention.
  2. Primary PCI for STEMIOstial RCA lesion within 5 mm of ostium*
  3. Coronary artery disease judged more suitable for surgical revascularization per guidelines and local heart team discussion.
  4. Another lesion in either the target vessel or non-target vessel is present that requires or has a high probability of requiring PCI within 9 months after the index procedure.
  5. Bifurcation lesions with planned or high probability of dual stent implantation*
  6. Target lesions located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft
  7. Heavily tortuous or angulated lesions*
  8. Lesions containing large thrombus*
  9. Total occlusions*
  10. Lesions present within 10mm of another lesion treated by PCI*
  11. Restenotic lesions* *Refers to target lesions. Non-target lesions not meeting these criteria may be treated as appropriate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02645799


Locations
Layout table for location information
Israel
Kaplan Medical Center
Rehovot, Israel
Sponsors and Collaborators
BIOrest Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Philippe Généreux, MD Cardiovascular Research Foundation (CRF)
Layout table for additonal information
Responsible Party: BIOrest Ltd.
ClinicalTrials.gov Identifier: NCT02645799    
Other Study ID Numbers: LA-II-02
First Posted: January 5, 2016    Key Record Dates
Last Update Posted: January 11, 2018
Last Verified: January 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No